

McAllen March 3rd, 2017—Wound Consultants of South Texas ( WCST) [www.woundconsultants.com](http://www.woundconsultants.com), a leader and innovator in wound management training and product choices announces the initiation of a strategic partnership with Integra Life Sciences Inc. Plainsboro, NJ. Distribution partnership began with WCST launch of Integra’s wound management and abdominal wall reconstruction products.

**SurgiMend®**, used by General, Plastic and Reconstructive and Trauma surgeons alike, offers clear advantages over synthetic and other biologic products for soft tissue repair and reconstruction. Derived from fetal or neonatal bovine dermis, this unique acellular dermal matrix provides surgeons with the widest flexibility to choose the most appropriate device thickness, strength, and size for each procedure, technique, and patient.

**PriMatrix®Dermal Repair Scaffold** is a unique scaffold for the management of the most challenging wounds. Derived from fetal bovine dermis, this novel acellular dermal matrix provides an ideal environment to support cellular repopulation and revascularization processes critical in wound healing. PriMatrix is particularly rich in Type III collagen, a collagen found in fetal dermis that is active in developing and healing tissues.

**Advanced Microcurrent Technology**® is exclusively sold under the name VolTAC Antimicrobial Wound Dressing in general wound care, plastic and reconstructive surgery, first and second degree burns, and other general/vascular surgery markets by Integra Life Sciences Corporation. Integra is a world leader in medical technology dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies in specialty surgical solutions, orthopedics, and tissue technologies.

**Introducing Integra® Omnigraft™ Dermal Regeneration Matrix,** The ONLY FDA approved product to regenerate native dermal tissue. Based on DRM technology, Omnigraft is an advanced bilayer dermal regeneration matrix indicated for the treatment of diabetic foot ulcers.

“We are excited about our strategic partnership with Integra Life Sciences” said managing partner and CEO of WCST, Cesar S. Lozano. “As a distributor partner, Integra Life Sciences offers WCST the expertise in Biologics and regenerative medicine that will position both companies for innovative and aggressive market penetration in the Rio Grande Valley-Laredo markets. Integra’s products are a whole new category of allograft tissue technology with advanced wound and dermal repair healing scaffolds and tissue reconstruction matrixes

This partnership is consistent with our long term goals of providing innovative products to surgeons, wound management physicians and their patients who suffer from chronic wounds and burns as well as injury due to trauma and disease.

Source: WCST/Integra.